Status:
WITHDRAWN
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Melanoma (Skin)
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or ...
Detailed Description
OBJECTIVES: Primary * Compare the impact of ipilimumab with vs without gp100 peptides emulsified with Montanide ISA-51 on clinical response in patients with previously treated, HLA-A\*0201 positive ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed stage IV melanoma
- HLA-A\*0201 positive disease
- Previously treated metastatic disease
- Clinically evaluable and measurable disease
- No mucosal or ocular melanoma
- No evidence of active brain metastases
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- WBC ≥ 2,500/mm³
- Absolute neutrophil count ≥ 1,000/mm³
- Absolute lymphocyte count ≥ 500/mm³
- Platelet count ≥ 75,000/mm³
- Hemoglobin ≥ 9 g/dL
- Creatinine \< 2.5 mg/dL
- AST ≤ 2 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
- Bilirubin normal (\< 3.0 mg/dL if Gilbert's syndrome is present)
- Hepatitis B surface antigen negative
- HIV negativity
- No hepatitis C virus antibodies
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other prior malignancy except for any of the following:
- Adequately treated basal cell or squamous cell skin cancer
- Superficial bladder cancer
- Carcinoma in situ of the cervix
- Any other cancer from which patient has been disease free for \> 5 years
- No active immune-mediated disease requiring active therapy with any form of steroid or immunosuppressive therapy
- No documented history of any of the following:
- Inflammatory bowel disease
- Regional enteritis
- Connective tissue disorders, such as systemic lupus erythematosus
- Rheumatoid arthritis
- Immune-mediated inflammatory eye disease
- Sjögren's syndrome
- Inflammatory neurologic disorder, such as multiple sclerosis
- Any immune-mediated disease that can cause life-threatening symptoms or severe organ/tissue damage, in the opinion of the principal investigator
- History of vitiligo or immune-mediated thyroiditis allowed
- Skin rashes associated with previous therapy allowed provided patient has recovered from treatment-related toxicity to \< grade 1
- No active infection
- No systemic hypersensitivity to any of the study drugs
- History of local reactions (e.g., delayed hypersensitivity or glaucomatous reactions) to Montanide ISA-51 allowed
- No underlying medical condition that, in the opinion of the investigator, would preclude study treatment
- PRIOR CONCURRENT THERAPY:
- At least 3 weeks since prior systemic treatment (6 weeks for nitrosoureas) and recovered
- No prior ipilimumab or gp100 vaccines
- More than 4 weeks since prior steroids
- No concurrent systemic or topical corticosteroids or immunosuppressive agents (e.g., cyclosporine or chemotherapy agents), including steroid enemas, inhaled steroids, or steroid eye drops
- Hormone-replacement therapy allowed
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00357461
Start Date
May 1 2006
Last Update
May 15 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.